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• MOC often carry genetic events indicating a targeted therapy and should be entered in basket trials of such agents.
• A distinct subset of MOC are estrogen receptor positive (~11%), suggesting hormonal therapy as an option.
• Mismatch repair deficiency is present in b1% of MOC; the role of checkpoint inhibitors is uncertain.
• Rarity of homologous recombination deficiency means MOC is unlikely to respond to platinum-based therapy/PARP inhibitors.☆ GAMuT collaborators (non-author contributors):Micha
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Available online 2 January 2020Objective.Mucinous ovarian carcinoma (MOC) is an uncommon ovarian cancer histotype that responds poorly
to conventional chemotherapy regimens. Although long overall survival outcomes can occur with early detection
and optimal surgical resection, recurrent and advanced disease are associated with extremely poor survival. There
are no current guidelines specifically for the systemic management of recurrent MOC. We analyzed data from a
large cohort of women with MOC to evaluate the potential for clinical utility from a range of systemic agents.el S Anglesio, George Au-Yeung, AlisonBrand, Georgia Chenevix-Trench, Stephen B Fox, Neville F Hacker, TomW Jobling, DavidG
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GenomicMethods.Weanalyzed gene copy number (n=191) andDNA sequencing data (n=184) fromprimaryMOC to
evaluate signatures of mismatch repair deficiency and homologous recombination deficiency, and other genetic
events. Immunohistochemistry data were collated for ER, CK7, CK20, CDX2, HER2, PAX8 and p16 (n = 117–166).
Results.Molecular aberrations noted in MOC that suggest a match with current targeted therapies include am-
plification of ERBB2 (26.7%) and BRAFmutation (9%). Observed genetic events that suggest potential efficacy for
agents currently in clinical trials include: KRAS/NRASmutations (66%), TP53missensemutation (49%), RNF43muta-
tion (11%), ARID1Amutation (10%), and PIK3CA/PTENmutation (9%). Therapies exploiting homologous recombina-
tion deficiency (HRD)may not be effective inMOC, as only 1/191 had a high HRD score. Mismatch repair deficiency
was similarly rare (1/184).
Conclusions.Although genetically diverse,MOC has several potential therapeutic targets. Importantly, the lack of
response to platinum-based therapy observed clinically corresponds to the lack of a genomic signature associated
with HRD, and MOC are thus also unlikely to respond to PARP inhibition.
© 2019 The Author(s). Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Mucinous ovarian carcinoma (MOC) is a rare histotype of epithelial
ovarian cancer (EOC), comprising 3–5% of EOC cases [1] with distinct
epidemiological differences including weaker associations with repro-
ductive and hormonal factors such as parity and oral contraceptive
use [2]. Diagnosis is often at an early stage, with surgical resection of
large unilateral tumors resulting in curative outcomes in many cases.
However, recurrent and in particular high-grade MOC are classically re-
sistant to conventional platinum/taxane therapy [1,3]. Median survival
for Stage III/IV disease is b15months compared to 41months for serous
and 51 months for endometrioid histologies [4]. Nonetheless, there are
no alternative approved treatment guidelines due to a lack of evidence
for efficacy. Internationally coordinated attempts to develop MOC clini-
cal trials to assess regimens designed formucinous gastrointestinal can-
cers unfortunately met with little success, with recruitment of these
rare cases proving to be highly challenging and overt clinical efficacy
not observed with the number of primary MOC cases included [5].
As a strategic and much needed step toward the development of
novel and targeted therapies for MOC, an international collaborative ef-
fort was formed to amass the largest known cohort of patients with an-
notated primaryMOCs.With investigation including extensive genomic,
transcriptomic, immunohistochemical and associated clinical data, we
aimed to evaluate current and alternate therapeutic options for this
rare and chemotherapy resistant tumor type.
2. Materials and methods
2.1. Cohort and pathology review
The GAMuT cohort has been described previously (Supplementary
Table 1) [6]. Centers and investigators with specialized ovarian cancer
interestwere approached to contribute to an international collaboration
to advance the knowledge and potential for mucinous ovarian cancers.
We obtained primary mucinous tumor samples, and metastases to the
ovary from other sites, from 12 different sources in four countries:
Australia: Royal Women's Hospital, the Victorian Cancer Biobank, The
Hudson Institute of Medical Research (all Victoria); Garvan Institute,
The Gynaecological Oncology Biobank at Westmead (New South
Wales); Queensland Institute for Medical Research (Queensland);
Australian Ovarian Cancer Study (Australia-wide); United Kingdom:
Southampton, and Edinburgh Cancer Research Centre; United States:
the Mayo Clinic (MN); Canadian Ovarian Experimental Unified Re-
source (COEUR, Quebec, Canada) and OVCARE (British Columbia,
Canada). All women provided informed consent for the use of their tis-
sue for research and this study was conducted in accordance with the
Declaration of Helsinki. All cases underwent expert pathology review
of at least one diagnostic slide by PEA,MC, JP, CBG orMK, aswell as clin-
ical review to confirm primary mucinous ovarian status. Clinical data
was collected by medical record review or tissue bank databases.Metastatic cases were mucinous tumors excluded as being primary
ovarian, mostly from the lower gastro-intestinal tract (n = 12), upper
gastro-intestinal tract (n = 9) or uterus (n = 4), 1 unknown.
2.2. Genetic data
DNAwas extracted frommicrodissected tumor cells as described [6].
DNA sequencing was performed using either whole genome (n = 5),
exome (n = 46) or targeted sequencing (n = 133) using an Agilent
SureSelect panel of 507 genes [6]. Four new cases analyzed with the
targeted panel are included that were not part of Cheasley et al. De-
tected variants were filtered as previously described to obtain a high–
confidence set of somatic variants. Data are available through the
European Genome Archive, submission EGAS00001003545. Mutation
figures generated by Mutation mapper in the cBioPortal [46].
Existing SNP array data were used when available for copy number
data. Otherwise copy number datawere obtained fromexome sequenc-
ing using AdTex [7], whole genome sequencing using FACETs (v0.5.6)
[8], and from the targeted sequencing panel using CopywriteR [9].
Thresholds were log2 ratios of ±0.2 for gains and losses, N0.6 for high
level gains and b−1 for homozygous deletions.
We evaluatedHRD bymutational signatures (exome/whole genome
only) [10] as well as copy number profiles (HRD score). HRD score was
calculated as described [11], except that calls were made manually due
to the diverse platforms used and the relative simplicity of most
genomes.
2.3. Immunohistochemistry
Immunohistochemical staining was performed by the Peter
MacCallum Cancer Centre Anatomical Pathology department using
standard clinical assays. For ER, we considered any staining in N1% of
cells to be positive. In 18/132 cases, ER staining status was obtained
from the pathology report. HER2 was scored according to international
guidelines for breast cancer, with 0 and 1+ considered negative, 2+
equivocal, and 3+ positive [12]. Final amplification status for equivocal
cases was determined by copy number analysis using sequencing or
SNP array data (Supplementary Table 2).
3. Results
The current cohort includes collected tissues and associated clinical
data from 12 archival sources from four different countries. Tissue
and/or data was collected from 202 MOC cases diagnosed between
1993 and 2017 (Table 1, Supplementary Table 1). Available clinical
data varied widely between sources, but in brief includes 157 early
stage (FIGO I-II) and 25 late stage (III-IV) cases. Sequencingdatawas ob-
tained by whole exome or whole genome sequencing (WES/WGS, n =
51) or using a targeted panel (n = 133). For comparison, we include
554 K.L. Gorringe et al. / Gynecologic Oncology 156 (2020) 552–560data for mucinous borderline tumors (n = 28) and mucinous tumors
that are metastases from extra-ovarian sites (n = 26).
3.1. Clinical management
A reviewofmanagementwas possible in 167of the 201 cases. A total
of 89 women (53%) were treated with surgery alone. For the cases with
chemotherapy details available, 72/74 (97%) women received a
platinum-based regimen, usually with a taxane in the first line (61/74,
82%) (Supplementary Fig. 1). Stage was strongly correlated with che-
motherapy provision, increasing from 33% of patients diagnosed with
Stage I MOC (41/124) to 83% for Stage II-IV (35/42). Data for second
and subsequent line therapy was limited to 23 cases, across which it
was notable that 16 different therapeutic regimens were prescribed, il-
lustrating the lack of treatment guidelines or consensus for themanage-
ment of this rare subset of ovarian cancer.
3.2. Homologous recombination deficiency
Homologous recombination deficiency (HRD) is an important clini-
cal correlate in ovarian cancer, strongly predicting response to
platinum-based therapies and PARP inhibition. Of 51 cases analyzed
by WES/WGS, no cases showed a point mutational signature of HRD
[10]. A single case carried a pathogenic BRCA2 mutation (8923;
Asn1784HisfsTer2), however, the allele frequency in tumor tissue was
only 0.23 and this case had a low copy-number derived HRD score
[11]. A co-existing TP53mutation had an allele frequency of 0.75, sug-
gestingmoderate tumor purity. Copy number loss and allelic imbalance
across chromosome13 indicates the loss-of-function BRCA2 allele, likely
germline, may have been lost in the tumor, with detection of the allele
attributable to the presence of non-tumor cells in the DNA extraction.
Therefore, while occurring in a BRCA2 carrier, the MOC appeared un-
likely to be an HRD-driven tumor. Copy number analysis of 191 cases
found just one with a profile complex enough to be classified as HRD-
high (Fig. 1A, score N 55; case WB87/8583). This HRD-high case had a
co-existing TP53mutation but no mutations in HRD-related genes. Pa-
thology review of diagnostic slides confirmed a high-grade mucinous
histology, including areas of borderline differentiation. Seven other
cases (3.8%) showed an HRD score of N42, placing them in a category
of possible responders [13].
3.3. Mismatch repair deficiency (MMR)
We evaluated the presence of MMR deficiency by mutation burden
analysis and identifying cases with mutations in any of the genes in
the pathway. One case of the 184 sequenced MOC (C1981) carried a
high mutation burden on targeted sequencing (N40 variants per Mb
[14], Fig. 1B) and a mutation inMSH6 (p.Arg1334SerfsTer7), although
no germline DNA was available to determine if this was somatic or
not. A secondMOC case (IC381) diagnosed at age 73 carried a germline
MSH6 variant (c.4065_4066insTTGA, p.Lys1358AspfsTer2); the tumorTable 1
– Cohort for genomic and IHC analysis.
Discovery sequencing
Mucinous borderline (n = 109) 9
Mucinous carcinoma (n = 198) 51
Grade
G1 21 (41%)
G2 22 (43%)
G3 8 (16%)
FIGO stage
I 37 (73%)
II 2 (4%)
III-IV 10 (20%)
Stage missing 2 (4%)
Extra-ovarian metastases (n = 36) 2did not carry an elevated number of mutations, nor LOH of the wild-
type allele. This variant occurred just 5 amino acids before the natural
termination codon, and thus its impact on MSH6 function may be min-
imal, with variants in a similar region classified as class 1 or 2 (benign)
in ClinVar [15], for example c.4068_4071dup (p.Lys1358Aspfs) is
classed “likely benign”. In contrast, 4/23 (17%) mucinous tumors meta-
static to the ovary (two colorectal, two endometrial) had a high muta-
tion burden and/or truncating mutation in one of MSH2 or MSH3.
Thus, as MOC cases harboring a high mutational burden are rare, single
agent therapywith immune checkpoint inhibitors is unlikely to be help-
ful for the majority.
3.4. HER2 and HER3
Copynumber datawere assessed in 191 cases, with ERBB2 amplifica-
tion found in 51 cases (26.7%). Amplifications were all high level and
focal, similar to those seen in breast and gastric cancer (Fig. 2, Supple-
mentary Fig. 2). IHC for HER2 was carried out in 61 of 191 cases. We
compared our copy number results derived from SNP arrays and se-
quencing to IHC and observed strong concordance of 3+ staining with
amplified and 0/1+ with non-amplified status in MOC (56/61, 91.8%).
Two cases were amplified but IHC negative (10673, 8981), and three
cases were either 2+ for IHC but not amplified (8488, VOA1675) or 2
+ and amplified (IC392). The reasons for the 2+ interpretation varied.
In twoMOC (IC392, VOA1675) this was likely due to a subclonal ampli-
fication whereby intense membranous IHC staining was only focally
present (Fig. 2C). Amplified/IHC positive cells may have been sampled
(IC392) or not (VOA1675) from the frozen tumor piece used for DNA
extraction. In contrast, for 8488 sequencing data indicated a low-level
copy number gain across all of 17q associated with 2+ staining.
In one MOC case (8981) with negative HER2 IHC from a tissue mi-
croarray (TMA), but positive copy number amplification by sequencing,
we repeated in situ analyses using whole sections. The results provide
evidence for intratumoral heterogeneity (Supplementary Fig. 2). The
sensitive sequencing assay was able to detect an amplification, but the
original IHC by TMA did not contain the part of the tumor that was am-
plified. Interestingly, this case was primarily a borderline tumor, and a
small group of cells showing abnormal morphology within the full sec-
tionwas the only area positive by CISH but showed onlymodest protein
staining (Supplementary Fig. 2).
We observed no ERBB2mutations, but a small number of ERBB3mu-
tated tumors were detected in our cohort (n = 8, 4.3% MOC, Supple-
mentary Fig. 3). The mutation distribution was similar to that seen in
COSMIC [16], with themajority of variants being observed in the recep-
tor and furin domains.
3.5. Other targetable genes
We assessed 184 cases for mutations in other potentially targetable
genes (Fig. 2). We observed 16 (8.7%) cases with BRAF mutations in
MOC, however, 7 of these cases did not carry the typical V600EmutationValidation sequencing Copy number IHC (ER)
18 39 80
133 191 132
62 (47%) 86 (45%) 61 (46%)
55 (42%) 79 (41%) 51 (39%)
16 (12%) 26 (14%) 20 (15%)
102 (77%) 147 (77%) 98 (74%)
8 (6%) 10 (5%) 9 (7%)
17 (13%) 25 (13%) 22 (17%)
6 (4%) 9 (5%) 3 (2%)
24 29 23
Fig. 1. Prevalence of DNA damage repair pathways. A. Homologous recombination deficiencywasmeasured as inMarquard et al. [11] (HRD Score) and shows thatMOC rarely have a score
above that used to predict response to platinum or PARP inhibitors (BRCA-deficient median and blue zone indicating HRD Score N42 that may respond to platinum from Telli et al. [13]).
Black diamond is the mean HRD Score. B. Mismatch repair deficiency is also rare, as indicated by themutation burden: Mutations per Mb, log10 transformed, black diamond is themean,
dashed line is a suggested threshold formismatch-repair deficiency detection fromNowak et al. [14]. Arrow,MOCwithMSH6mutation, arrowheads, extra-ovarianmetastases (EOM)with
MMR gene mutations, *, MOC withMSH6mutation that is likely non-pathogenic. BEN, benign mucinous tumor, MBT, mucinous borderline tumor.
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tation (although three of these were atypical but likely still oncogenic:
p.Lys5Asn, p.Gly13dup and p.Gln61His).KRASmutationswere observed
in 118/184 MOC (64%) and NRAS in 3/184 cases (1 also with a KRAS
mutation).
Fifteen of 184 MOC and 4/39 mucinous borderline tumors were
found to harbor mutations in PIK3CA. However, the mutation spectrum
was very different to that in COSMIC, with 8 variants in the PI3-kinase
domain, just one at the p.H1047 hotspot and two nearby, and the re-
maining 8 at other unusual locations in the first 500 amino acids (Sup-
plementary Fig. 3). In COSMIC, b20% of themutations are outside of the
hotspots in exons 9 and 20 (+/− 5 amino acids), but these comprised
10/19 (53%) of the mutations we observed. This 2.5-fold higher rate of
non-hotspot mutations is significantly different from expected based
on COSMIC (p = 0.003, binomial exact two-tailed test). Two of 185
MOChad inactivating events in PTEN (1 truncatingmutation, 1 homozy-
gous deletion) that were exclusive of PIK3CAmutations.
Othermolecularly targeted agents that are not currently in the clinic,
but are in clinical trials include Wnt-pathway inhibitors (RNF43muta-
tions), mutant p53 reactivating drugs (TP53 missense mutations) and
epigenetic modifiers (ARID1A mutations). Mutations in these genes
are detected in our cohort at varying frequencies (Table 2).
We evaluated whether any mutations were enriched in grade 3 tu-
mors, as a proxy for the infiltrative subtype of MOC that is at higher
risk of recurrence [17], and found that mutations in PIK3CAwere more
common in grade 3 than other grades (grade 3 6/24 versus grade 1, 4/
83 and grade 2, 5/77, p = 0.049, Fishers exact test with Benjamini-
Hochberg correction for multiple testing). Conversely, mutations in
RNF43 were absent in grade 3 cases (corrected p value = 0.003).
3.6. Estrogen receptor (ER) status
We evaluated ER expression in 132 MOC cases, with positive stain-
ing seen in 14 cases (10.6%, Supplementary Fig. 4). There was a trend
for ER positivity to increase with grade from 5% of grade 1 cases up to
20% of grade 3 cases (p = 0.035, Cochran-Armitage test for trend,Z =−2.10). In contrast, just 1/80 borderline cases (1.25%) were ER+
(Fig. 2C). ER staining in MOC was positively associated with tumor
PAX8 staining, with 8/12 ER+ cases also PAX8+ (Supplementary
Fig. 4). The genetic events in this group were distinct, with significantly
fewer TP53mutations and CDKN2A losses in ER+MOC and significantly
more CTNNB1mutations (Supplementary Fig. 4).
4. Discussion
In molecular profiling of MOC, we have identified current therapies
that are unlikely to be effective (cisplatin, PARPi, immune checkpoint
inhibitors), and in contrast, we highlight a range of targeted therapies
worthy of focus, which could have an impact in the near future on indi-
vidual cases of MOC (Table 2). The low rate of HRD inMOC is consistent
with previous studies showing a generally stable genomic profile and a
low rate of germline BRCA1/2mutations [18]. It is also consistent with
the reported lack of response to platinum-based therapies, although
wewere unable to directly correlate HRD scores with response. It is im-
portant to highlight that we should avoid prescribing therapy for pa-
tients with a rare cancer if there is evidence for a high probability that
patients are highly unlikely to receive benefit. Instead, such patients
would be better off having investigation formolecularmatching of ther-
apy, if evidence suggests the likelihood of targetable aberrations in their
rare tumor type [19].
Early reports suggested an association of MMR deficiency with non-
serous ovarian cancer histotypes, including mucinous carcinoma [20].
This indication, together with the potential for MMR deficiency in gas-
trointestinal/endometrial origin tumors with adnexal metastasis
[21,22], means it is not uncommon for clinicians to request immunohis-
tochemistry of MMR proteins in MOC. More recent studies have sug-
gested that MMR-deficient ovarian cancer is only common in the
endometrioid histotype [23,24]. The difference in the rates of MMR de-
ficiency observed in our study compared to older cohorts may be ex-
plained by our careful selection of primary MOC, whereas older
studies will include cases of endometrial and colorectal origin. The de-
tection of MMR deficiency in a fairly high proportion of our non-
Fig. 2.Targetable events inmucinous ovarian cancer. A. Genetic events potentially targetable inMOC.MBT=mucinous borderline tumorn=27, G1MOCn=83, G2MOCn=78, G3MOC
n= 24. Mutation type: Amp= Amplification (ERBB2 only); HomDel = Homozygous deletion (CDKN2A only). B. ER immunohistochemistry status by MOC grade. C. ERBB2 amplification
and HER2 immunohistochemistry. Case 15417 showing concordance of 3+ staining and high-level amplification (Scale bar 100 μm). Case IC392 showing HER2 heterogeneity (Scale bar
200 μm). Arrows indicate location of ERBB2 gene. D. Percentage of cases with the number of genes (from A) affected by mutation or copy number.
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Table 2
Potentially targetable events in MOC.
Genetic event Na in MOC (%) Potential therapy
Currently in the clinic for other cancer types 79 (42.9%)
ERBB2 amplification 51 (26.7%) Anti Her2 monoclonal antibody therapy, Anti Her2 Mab conjugate therapies, Anti-Her2 tyrosine kinase inhibitors
BRAFmutation (any)
BRAFmutation (V600E)
16 (8.7%)
9 (4.9%)
BRAF inhibitors
High HRD score (N55)
Moderate HRD score (42–55)
1 (0.5%)
7 (3.8%)
Platinum salts, PARP inhibitors
ER positivity 14 (10.6%) Anti-estrogens, CDK4/6 inhibition
Mismatch repair deficiency 1 (0.5%) Immune checkpoint inhibitors
Currently in trials for other cancer types 167 (90.8%)
KRAS, NRASmutation 118, 3 (65.8%) Broad spectrum RAS/RAF inhibition, MEK inhibition
TP53missense mutation 90 (48.9%) Mutant p53 reactivators
RNF43mutation 21 (11.4%) FZD inhibition, PORCN inhibitors
ARID1Amutation 19 (10.3%) Epigenetic modifiers (e.g. BET inhibitors, EZH2 inhibitors), ATR inhibitors
PIK3CAmutation, PTEN inactivating 15, 2 (9.2%) PI3-kinase inhibitors, AKT inhibitors
ERBB3mutation 8 (4.3%) Anti-Her2 tyrosine kinase inhibitors, anti-Her3 Mab conjugate therapies
Not yet targetable
CDKN2A inactivating 82 (44.6%)
TP53 truncating/ESS mutation 30 (16.3%)
a Mutation data denominator = 184; copy number denominator = 191.
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gest little benefit from reflex MMR IHC testing for MOC unless
there was a strong suspicion of extra-ovarian origin. The low rate
of MMR-deficiency suggests that single agent immune checkpoint
inhibition may have limited potential benefit, however the immune
microenvironment remains unexplored in MOC, and it is necessary
to assess whether these tumors are immunologically “hot” by other
mechanisms and could therefore benefit [25].
Previous data in MOC found that ERBB2 amplificationwas present in
~20% of cases [26], and our data found a similar proportion. Targeting
HER2 in MOC has been attempted anecdotally with mixed results [26]
but a clinical trial failed to recruit enough patients. The high-level and
focal nature of the amplifications and the strong over-expression in
mostMOC suggests this could be a viable target, however, response can-
not be guaranteed. We observed substantial heterogeneity in the pres-
ence of amplification, and in the strength of HER2 positive staining by
IHC (e.g. 10405, Supplementary Fig. 2). ERBB2 amplification appears to
be a relatively late event in MOC development, as it occurs significantly
less frequently in borderline tumors. Heterogeneity within the carci-
noma component may indicate firstly, that treatment with anti-HER2
therapies may not be effective on all tumor cells and secondly, that re-
currence testing may be required for metastatic disease. Additionally,
anti-HER2 antibody monotherapy (e.g. trastuzumab) is most effective
in the presence of a strong immune infiltrate [27] and a combination
with a small molecule tyrosine kinase inhibitor may be required in tu-
mors with low immune response. Alternatively, a conjugate therapy
that exploits an antibody to the overexpressed HER2 to deliver a
toxic payload may be of greater efficacy (e.g. Trastuzumab-DM1 or
Trastuzumab-deruxtecan). In addition, the strong co-existence of
TP53 mutation with ERBB2 amplification provides a strong rationale
for attempting p53 normalizing therapies [28] in combination with
anti-HER2 therapy.
It is unclear at present whether mutations in ERBB3 lead to long-
term responses by small molecular inhibitors. A recent basket trial did
not see any responses to neratinib across several tumor types [29]. In
addition, the same trial saw responses in ERBB2mutated tumors, most
often in breast cancer but not colorectal cancer. Differences in response
were also observed depending on themutation type and location. In the
MOSCATO trial, the best response of an ERBB3mutated tumorwas a par-
tial response to combined trastuzumab and lapatinib, while stable dis-
ease was recorded in 7/9 patients treated with afatinib (n = 2),
combined trastuzumab and lapatinib (n = 2), lapatinib alone (n = 1)
or other combinations (n = 2) [30]. The best responses to lapatinib
were in tumors with mutations in the tyrosine kinase domain [30],
however only one of the mutations detected in our MOC cohort waslocated in this domain. The small percentage of MOC with ERBB3muta-
tions could present an alternative therapeutic opportunity but will
likely require combination therapy.
BRAF inhibitors are in current clinical practice formelanomaand show
promise for low-grade serous ovarian carcinoma [31], but have shown lit-
tle efficacy in colorectal carcinoma [32]. Whether MOCwould respond to
this class of agent remains unclear but again may be worthy of explora-
tion. The high rate of non-V600E mutations in MOC suggests a lower po-
tential response to existing BRAF inhibitors such as vemurafinib, butMOC
may be responsive to new combined RAS-RAF inhibitors. BRAF, NRAS and
KRASmutant cases together comprise over 70% ofMOC and thesewomen
could now be included in combination clinical trials of dual RAS/RAF in-
hibitors such as BGB-283 [33] (e.g. NCT03905148). Similarly, while we
observed an overall mutation rate of ~9% in PIK3CA/PTEN, suggesting
that targeting the PI3-kinase pathway is worth considering during ther-
apy selection [34], the clinical significance of the frequent PIK3CAmuta-
tions outside of the usual hotspots is unclear. Inhibitors targeting the
PI3-kinase pathway are in clinical development for the management of
advanced endometrial, breast and other cancer types (for example
alpelisib (PIK3CA-mutated) and buparlisib (pan-PI3K) [35]), with some
inhibitors not limited specifically to the PI3kinase domains, but others
more broadly targeting the AKT/PTEN/PI3K pathways. One of the most
common genetic events in MOC is CDKN2A inactivation, however,
whether this gene is a biomarker for response to CDK4/6 inhibition re-
mains an open question that may be tumor-type specific [36].
Low-grade serous and endometrioid ovarian carcinomas have high
frequencies of ER protein expression [37]. It has been suggested that
these histotypes may respond to hormonal therapy [38–40]. The per-
centage of ER+ cases we observed (10.6%) is consistent with a recent
OTTA study, which found that 16% of MOC had strong ER expression
[37], but others report rates as low as 4% up to 19% [41–44]. None of
theMOC cases in our cohort appear to have received hormonal therapy,
hence hormonal response data within this cohort is unknown. It is
worth noting that this subset of ER+ MOC in our cohort appears to be
distinct from ER- MOC, based on their genetic features. We speculate
that these ER+ cases could represent a subset of MOC with an origin
in endometriosis, in a spectrum of tumors incorporating those previ-
ously known as “seromucinous” or “endocervical” types. Unfortunately,
the clinical and histopathology data with respect to the presence or ab-
sence of endometriosis was incomplete in our cohort, and we could not
assess this potential association. An alternative explanation is that some
of these ER+ cases could in fact have been misdiagnosed endometrioid
carcinomas, a recently recognized issue [44]. Data from Rambau et al.
showed that the seromucinous type most often resembled an
endometrioid ovarian carcinoma at a molecular level [45]. The ER+
558 K.L. Gorringe et al. / Gynecologic Oncology 156 (2020) 552–560MOC in our cohort were intermediate on a molecular level, with more
CTNNB1mutations than ER- MOC, but more TP53mutations and fewer
PIK3CA mutations than endometrioid carcinomas (Supplementary
Fig. 4). Inclusion of ER (and PR [44]) in the diagnostic work-up for
MOC in the future will therefore be important, both to exclude
misdiagnosed endometrioid cases and for therapeutic stratification. In-
clusion of patientswith ER positiveMOC in trials, for example basket tri-
als of Aromatase Inhibitors, would provide useful information.
In summary, this exploration of themolecular therapeutic landscape
of MOC is the largest undertaken to date and has identified many ave-
nues for investigation. We have summarized these avenues in Fig. 3. If
we consider all variants reported in this study as potentially targetable,
plus the known targets in other cancer types (BRAF and ERBB2/3), then
the proportion of cases with at least one theoretically targetable event
was 93.5%, with 65% of cases having two or more targetable events.
However, there is currently no evidence for these therapies in MOC.Fig. 3. Clinical pathway for therapy choice in MOC. We suggest that high-risk disease (grade 3
using a suitable panel method, since these are unlikely to respond completely to the adjuvant
non-high risk disease, genomic testing should also be performed, preferably on recurrence tu
tissue could be used. ER, estrogen receptor; HRD, homologous recombination deficiency; TMBGiven the tissue specificity of some targeted therapies, preclinical data
using genomically characterized patient-derived models in vitro and
in vivo are urgently required to evaluate efficacy. Nonetheless, multiple
clinical trials with specific molecular targets are in progress andwomen
diagnosed with MOC would greatly benefit from trials that performed
DNA sequencing to identify the most suitable targeted therapy
(Table 2). In addition, in order to maximize benefit, such trials should
be targeted to those agents with the greatest pre-clinical efficacy. Clini-
cal response, and lack of response, to targeted therapies must be re-
ported along with biomarker information to build an evidence base in
humans. Importantly, 23% of women were found to have MOC harbor-
ing three ormore targetablemutationswhichmay increase their chance
of responding to targeted therapy combinations in the future [19]. This
approach contrasts with current practice of prescribing platinum-based
chemotherapy, which provides little benefit but imposes considerable
toxicity. While these potential targets likely over-represent the reality/advanced stage/infiltrative subtype) should be pre-emptively tested for genomic events
chemotherapy that will be offered while genomic testing is performed. On recurrence of
mor tissue if this is available through surgical debulking or biopsy. If not, primary tumor
, tumor mutational burden; “i”, inhibitor. TKi, tyrosine kinase inhibitor.
559K.L. Gorringe et al. / Gynecologic Oncology 156 (2020) 552–560of tumor response, for a tumor type with such poor outcomes and no
specific treatment recommendations the potential for therapeutic ex-
ploration appears bright.
Supplementary data to this article can be found online at https://doi.
org/10.1016/j.ygyno.2019.12.015.
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